Drugs / RAY121
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06723106 | Dec 2024 → Feb 2028 expected | Behcet disease, antiphospholipid syndrome, autoimmune thrombocytopenia, bullous pemphigoid +2 | Chugai Pharmaceutical | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06371417 | Aug 2024 → Jun 2026 overdue | Behcet disease, antiphospholipid syndrome, autoimmune thrombocytopenia, bullous pemphigoid +2 | Chugai Pharmaceutical | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAY121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06371417 ↗ |
| Action | Inhibit | “a inhibitor of classical complement pathway” NCT06371417 ↗ |
| Route | Other | “Injection” NCT06371417 ↗ |